Showing results (71-80 of 154) with videos related to

Sort By:
Pageof 16
Open Forum Infectious Diseases|March 30, 2022
Long-Term Efficacy, Safety, and Durability of Cabotegravir and Rilpivirine as 2-Drug Oral Maintenance Therapy After 6 Years of StudyKenneth C Sutton, Jerome De Vente, Roger Leblanc, et al.
The Journal of Infectious Diseases|January 13, 2010
Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trialJamal Suleiman, Barry S Zingman, Ricardo Sobhie Diaz, et al.
AIDS (London, England)|March 18, 2011
Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infectionCalvin Cohen, Richard Elion, Peter Ruane, et al.
Plos One|March 4, 2014
HIV-1 transmission patterns in antiretroviral therapy-naïve, HIV-infected North Americans based on phylogenetic analysis by population level and ultra-deep DNA sequencingLisa L Ross, Joseph Horton, Samiul Hasan, et al.
AIDS Research and Human Retroviruses|February 5, 2008
Adherence to enfuvirtide and its impact on treatment efficacyJürgen Rockstroh, Edwin Dejesus, Lucille Donatacci, et al.
JAMA|July 14, 2004
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trialJoel E Gallant, Schlomo Staszewski, Anton L Pozniak, et al.
The Journal of Infectious Diseases|February 13, 2008
Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patientsJacob Lalezari, Gopal K Yadavalli, Michael Para, et al.
The Lancet. HIV|February 22, 2017
Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trialPaul E Sax, Edwin DeJesus, Gordon Crofoot, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 13, 2004
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trialEdwin DeJesus, Debra McCarty, Charles F Farthing, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 24, 2006
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysisAnton L Pozniak, Joel E Gallant, Edwin DeJesus, et al.
Pageof 16